- Home
- RDVT vs MREO Comparison
RDVT vs MREO Comparison
Compare RDVT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- MREO
- Stock Information
- Founded
- RDVT 2017
- MREO 2015
- Country
- RDVT United States
- MREO United Kingdom
- Employees
- RDVT N/A
- MREO N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- MREO Health Care
- Exchange
- RDVT Nasdaq
- MREO Nasdaq
- Market Cap
- RDVT 550.8M
- MREO 482.5M
- IPO Year
- RDVT N/A
- MREO N/A
- Fundamental
- Price
- RDVT $38.84
- MREO $2.85
- Analyst Decision
- RDVT Strong Buy
- MREO Strong Buy
- Analyst Count
- RDVT 1
- MREO 6
- Target Price
- RDVT $25.00
- MREO $7.83
- AVG Volume (30 Days)
- RDVT 104.8K
- MREO 917.3K
- Earning Date
- RDVT 02-27-2025
- MREO 03-26-2025
- Dividend Yield
- RDVT 0.77%
- MREO N/A
- EPS Growth
- RDVT N/A
- MREO N/A
- EPS
- RDVT 0.36
- MREO N/A
- Revenue
- RDVT $70,685,000.00
- MREO $1,000,000.00
- Revenue This Year
- RDVT $24.88
- MREO N/A
- Revenue Next Year
- RDVT $14.52
- MREO N/A
- P/E Ratio
- RDVT $109.49
- MREO N/A
- Revenue Growth
- RDVT 21.43
- MREO N/A
- 52 Week Low
- RDVT $16.56
- MREO $2.53
- 52 Week High
- RDVT $43.44
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- RDVT 50.72
- MREO 38.17
- Support Level
- RDVT $38.57
- MREO $2.82
- Resistance Level
- RDVT $41.80
- MREO $2.99
- Average True Range (ATR)
- RDVT 1.90
- MREO 0.13
- MACD
- RDVT -0.04
- MREO 0.01
- Stochastic Oscillator
- RDVT 41.92
- MREO 14.74
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses, and assets.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).